Search

Your search keyword '"Kim, Nam Doo"' showing total 387 results

Search Constraints

Start Over You searched for: Author "Kim, Nam Doo" Remove constraint Author: "Kim, Nam Doo"
387 results on '"Kim, Nam Doo"'

Search Results

8. Discovery of a selective inhibitor of doublecortin like kinase 1

11. Data from Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance

12. Data from Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer

13. Supplementary Data from Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance

14. Supplementary Methods from Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer

15. Supplementary Table S1 from Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer

16. Supplementary Figure S1 from Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer

17. Supplementary Figure Legends from Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer

18. Supplementary Materials and Methods from Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance

27. Abstract LB521: Antitumor activity of potent RAF inhibitors in solid tumors with activated RAS-RAF axis

28. p21‐activated kinase 4 inhibition protects against liver ischemia/reperfusion injury: Role of nuclear factor erythroid 2‐related factor 2 phosphorylation

30. Identification of Thiazolo[5,4- b ]pyridine Derivatives as c-KIT Inhibitors for Overcoming Imatinib Resistance.

33. Abstract P2-13-15: VRN101396, a brain-permeable HER2 inhibitor, shows the anti-tumor activity in preclinical HER2-positive cancer models

34. Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance

35. Novel Macrocyclic Peptidomimetics Targeting the Polo-Box Domain of Polo-Like Kinase 1

39. Abstract P234: ORIC-114, an orally bioavailable, irreversible kinase inhibitor, has superior brain penetrant properties and enhanced potency in preclinical studies of HER2-positive breast cancer

41. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor

44. Identification of Thieno[3,2-d]pyrimidine Derivatives as Dual Inhibitors of Focal Adhesion Kinase and FMS-like Tyrosine Kinase 3

45. Abstract 1466: ORIC-114, a brain penetrant, orally bioavailable, irreversible inhibitor selectively targets EGFR and HER2 exon20 insertion mutants and regresses intracranial NSCLC xenograft tumors

46. Abstract LB139: VRN10, Discovery of Potent Irreversible HER2 Kinase Inhibitors with Intracranial Activity

Catalog

Books, media, physical & digital resources